NeuroSense Announces Completion of PARADIGM Study Highlighting PrimeC's Significant Efficacy and Survival Benefits in ALS

CAMBRIDGE, Mass., Dec. 4, 2024 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a late-clinical stage biotechnology company developing novel treatments for severe neurodegenerative diseases, is pleased to announce today statistically significant positive results from the 18-month data analysis of the PARADIGM study, evaluating the efficacy of PrimeC in the treatment of Amyotrophic Lateral Sclerosis (ALS). These results highlight a significant improvement in ALS Functional Rating Scale-Revised (ALSFRS-R) scores and survival rates for patients receiving PrimeC from the start compared to those who started on placebo.

Read more at prnewswire.com